Comparison of Different Doses of Verteporfin Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy
This is a prospective, randomized and controlled clinical trial of photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSC). The patients who met the inclusion criteria were randomly divided into 50% dose PDT treatment group and 70% dose PDT treatment group. The primary treatment success rate and adverse event rate of the two groups were compared by optical coherence tomography (OCT), and then the best PDT treatment scheme for chronic CSC was summarized.
• 18-75 years old, regardless of gender;
• Meet the diagnostic criteria of central serous chorioretinopathy;
• The course of CSC (subject to the symptoms of this disease) is more than 3 months;
• Patients with simultaneous diseases of both eyes were included in those with more subretinal fluid.